



CERTIFICATE OF ANALYSIS




Product Details

Product name:	Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab)	Lot.No.:	P72064
Target:	CTLA-4 / CD152	Catalog:	CHA032
Target Accession:	P16410	Concentration :	1 mg/mL
Clonality:	Monoclonal	Isotype:	Human IgG1
Reactivity:	Human / Cynomolgus CTLA-4	Molecular Weight (kDa) :	145.38 kDa
Application:	FCM, WB, Neutralization, In Vivo, ELISA	Endotoxin:	<1 EU/mg
Formulation:	Liquid: 100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Purification:	Protein A


Data

Purity: SDS-PAGE

Purity: SEC-HPLC




Anti- Human CTLA-4 (Ipilimumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti- Human CTLA-4 (Ipilimumab) is 99.37%, determined by SEC-HPLC.

Bioactivity: FACS



Human CTLA-4 & PD-1-expressing CHO-K cells were stained with Anti-Human CTLA-4 (Ipilimumab) , with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.2270 ug/mL.

Research in vivo



Anti- Human CTLA-4 (Ipilimumab) inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.

The products are for research use only. Not for use in diagnostic procedures.